Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of IBI133 monotherapy in advanced solid tumors
CTR20241441Phase 2Completed
- Sponsor
- InnoCare Pharma
- Start
- Apr 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of IBI133 in Nonhematologic neoplasms, sponsored by InnoCare Pharma. Started Apr 2024; status: completed.
02
Drugs
IBI133
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20241441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241441.